---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/277507707.md"
description: "Eton Pharmaceuticals shares are trading higher after the company expanded its Rare Disease Portfolio through the acquisition of U.S. Commercialization Rights to HEMANGEOL Oral Solution. Also, HC Wainwright & Co. maintained its Buy rating on the stock and raised the price target from $35 to $37."
datetime: "2026-03-02T17:28:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277507707.md)
  - [en](https://longbridge.com/en/news/277507707.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277507707.md)
---

# 

Eton Pharmaceuticals shares are trading higher after the company expanded its Rare Disease Portfolio through the acquisition of U.S. Commercialization Rights to HEMANGEOL Oral Solution. Also, HC Wainwright & Co. maintained its Buy rating on the stock and raised the price target from $35 to $37.

### Related Stocks

- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [ETON.US](https://longbridge.com/en/quote/ETON.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)

## Related News & Research

- [CRISPR Therapeutics Touts “Second Phase” After Casgevy, Eyes 6 Data Readouts in 6–12 Months](https://longbridge.com/en/news/282582813.md)
- [Should Positive Elsunersen Data And Relutrigine Priority Review Shift the Narrative for Praxis (PRAX) Investors?](https://longbridge.com/en/news/282419526.md)
- [08:00 ETLynk Pharmaceuticals Announces NDA Acceptance for Zemprocitinib by NMPA](https://longbridge.com/en/news/282340368.md)
- [PolyPid To Present New Phase 3 SHIELD II Data On D-PLEX100 At ESCMID 2026](https://longbridge.com/en/news/282665678.md)
- [<![CDATA[FDA Issues CRL to Replimune for RP1 Biologics License Application for Advanced Melanoma Treatment ]]>](https://longbridge.com/en/news/282567251.md)